Aller directement au menu principal Aller directement au contenu principal Aller au pied de page
Cortica

Perspective

Vol. 3 No. 2 (2024): La multidisciplinarité de la psychologie de la santé & des neurosciences

L’effet bénéfique de l’expérience mystique dans le trouble dépressif caractérisé à travers l’utilisation de la psilocybine: Une revue systématique de la littérature

  • Alessia Calanchini
DOI
https://doi.org/10.26034/cortica.2024.6098
Soumise
September 20, 2024
Publié-e
2024-09-21

Résumé

La dépression est l'un des principaux problèmes de santé publique actuels. Malgré la recherche, il est encore difficile de comprendre tous les mécanismes qui sous-tendent le développement de ce trouble. C'est pourquoi tous les traitements utilisés ne sont pas efficaces, ce qui conduit inévitablement à des formes de dépression résistantes aux traitements. Depuis une vingtaine d'années, la reprise des recherches sur les substances psychédéliques semble prometteuse : en effet, leur pouvoir thérapeutique dans divers troubles mentaux, dont la dépression, a été mis en évidence. L'objectif de cet article est d'étudier l'impact bénéfique de l'expérience mystique induite par la psilocybine sur la dépression, compte tenu de la littérature actuelle. Pour ce faire, une recherche systématique a été menée en utilisant la méthode PRISMA et cinq études ont été prises en compte. Les résultats montrent effectivement le rôle de l'expérience mystique dans la réduction de la dépression. Toutefois des incohérences subsistent dans la définition de certains concepts. Les études futures devraient mieux définir le concept d'expérience mystique et les bienfaits potentiels qui peuvent être appliqués non seulement à la dépression mais aussi à divers troubles.

Références

  1. Al-Naggar, R. A., Alshaikhli, H., & Erlam, G. (2021). Effectiveness of psilocybin on depression: a qualitative study. Electronic Journal of Medicine, 18(3), em296. https://doi.org/10.29333/ejgm/10862
  2. American Psychiatric Association. (2013). Diagnostic and statistical manual of mental disorders (5th ed.). https://doi.org/10.1176/appi.books.9780890425596
  3. Arab-Zozani, M., & Hassanipour, S. (2020). Following PRISMA in a systematic review: Obligation or authority?. International Journal of Preventive Medicine, 11(1), 70. DOI: 10.4103/ijpvm.IJPVM_400_19
  4. Artin, H., Zisook, S., & Ramanathan, D. (2021). How do serotonergic psychedelics treat depression: The potential role of neuroplasticity. World Journal of Psychiatry, 11(6), 201. DOI:10.5498/wjp.v11.i6.201
  5. Asp, E., Ramchandran, K., & Tranel, D. (2012). Authoritarianism, religious fundamentalism, and the human prefrontal cortex. Neuropsychology, 26(4), 414–421. https://doi.org/10.1037/a0028526
  6. Athira, K. V., Bandopadhyay, S., Samudrala, P. K., Naidu, V. G. M., Lahkar, M., & Chakravarty, S. (2020). An Overview of the Heterogeneity of Major Depressive Disorder: Current Knowledge and Future Prospective. Current Neuropharmacology, 18(3), 168–187. DOI: 10.2174/1570159X17666191001142934
  7. Bains, N., & Abdijadid, S. (2020). Major depressive disorder. StatPearls. https://www.ncbi.nlm.nih.gov/books/NBK559078/
  8. Barrett, F. S., Bradstreet, M. P., Leoutsakos, J.-M. S., Johnson, M. W., & Griffiths, R. R. (2016). The Challenging Experience Questionnaire: Characterization of challenging experiences with psilocybin mushrooms. Journal of Psychopharmacology (Oxford, England), 30(12), 1279–1295. https://doi.org/10.1177/0269881116678781
  9. Barrett, F. S., & Griffiths, R. R. (2018). Classic Hallucinogens and Mystical Experiences : Phenomenology and Neural Correlates. Current Topics in Behavioral Neurosciences, 36, 393-430. https://doi.org/10.1007/7854_2017_474
  10. Barton, Y. A., & Miller, L. (2015). Spirituality and positive psychology go hand in hand: An investigation of multiple empirically derived profiles and related protective benefits. Journal of Religion and Health, 54, 829-843. https://doi.org/10.1007/s10943- 015-0045-2
  11. Bathina, S., & Das, U. N. (2015). Brain-derived neurotrophic factor and its clinical implications. Archives of medical science, 11(6), 1164-1178. DOI: Arch Med Sci 2015; 11, 6: 1164-1178
  12. Bernard, J. (2016). Ayahuasca : l’importance du cadre et de l’intention lors de prise de psychédéliques. Psychotropes, 22, 81-100. https://doi.org/10.3917/psyt.222.0081
  13. Boku, S., Nakagawa, S., Toda, H., & Hishimoto, A. (2018). Neural basis of major depressive disorder: Beyond monoamine hypothesis. Psychiatry and Clinical Neurosciences, 72(1), 3–12. https://doi.org/10.1111/pcn.12604
  14. Bottemanne, H., Berkovitch, L., Gasnier, M., & Mallet, L. (2023). La médecine psychédélique : Renouveau des traitements d’action rapide contre la dépression ? L’information Psychiatrique, 99(10), 685–692. https://doi.org/10.1684/ipe.2023.265
  15. Bradford, D. T. (2013). Emotion in mystical experience. Religion, Brain & Behavior, 3(2), 103–118. https://doi.org/10.1080/2153599X.2012.703004
  16. Braunsdorf, M., Blazquez Freches, G., Roumazeilles, L., Eichert, N., Schurz, M., Uithol, S., Bryant, K. L., & Mars, R. B. (2021). Does the temporal cortex make us human? A review of structural and functional diversity of the primate temporal lobe. Neuroscience & Biobehavioral Reviews, 131, 400–410.
  17. https://doi.org/10.1016/j.neubiorev.2021.08.032
  18. Breeksema, J. J., & Van Elk, M. (2021). Working with Weirdness: A Response to “Moving
  19. Past Mysticism in Psychedelic Science”. ACS Pharmacology & Translational Science,
  20. (4), 1471–1474. https://doi.org/10.1021/acsptsci.1c00149
  21. Cai, N., Choi, K. W., & Fried, E. I. (2020). Reviewing the genetics of heterogeneity in
  22. depression: operationalizations, manifestations and etiologies. Human Molecular
  23. Genetics, 29(R1), R10-R18. https://doi.org/10.1093/hmg/ddaa115
  24. Calvey, T., & Howells, F. M. (2018). An introduction to psychedelic neuroscience. Progress in
  25. Brain Research, 242, 1-23. DOI: 10.1016/bs.pbr.2018.09.013
  26. Carbonaro, T. M., Bradstreet, M. P., Barrett, F. S., MacLean, K. A., Jesse, R., Johnson, M. W.,
  27. & Griffiths, R. R. (2016). Survey study of challenging experiences after ingesting psilocybin mushrooms: Acute and enduring positive and negative consequences. Journal of Psychopharmacology (Oxford, England), 30(12), 1268–1278. https://doi.org/10.1177/0269881116662634
  28. Carhart-Harris, R. L., Bolstridge, M., Rucker, J., Day, C. M., Erritzoe, D., Kaelen, M., Bloomfield, M., Rickard, J.A., Forbes, B., Feilding, A., Taylor, D., Pilling, S., Curran, V.H., & Nutt, D. J. (2016). Psilocybin with psychological support for treatment- resistant depression: an open-label feasibility study. The Lancet Psychiatry, 3(7), 619- 627. https://doi.org/10.1016/S2215-0366(16)30065-7
  29. Carhart-Harris, R. L., Bolstridge, M., Day, C. M. J., Rucker, J., Watts, R., Erritzoe, D. E., Kaelen, M., Giribaldi, B., Bloomfield, M., Pilling, S., Rickard, J. A., Forbes, B., Feilding, A., Taylor, D., Curran, H. V., & Nutt, D. J. (2018a). Psilocybin with psychological support for treatment-resistant depression: Six-month follow-up. Psychopharmacology, 235(2), 399–408. https://doi.org/10.1007/s00213-017-4771-x
  30. Carhart-Harris, R. L., Roseman, L., Haijen, E., Erritzoe, D., Watts, R., Branchi, I., & Kaelen, M. (2018b). Psychedelics and the essential importance of context. Journal of Psychopharmacology, 32(7), 725-731. https://doi.org/10.1177/0269881118754710
  31. Carod-Artal, F. J. (2015). Hallucinogenic drugs in pre-Columbian Mesoamerican cultures. Neurología (English Edition), 30(1), 42–49. https://doi.org/10.1016/j.nrleng.2011.07.010
  32. Chambon, O., & Marie-Cardine, M. (2019). Chapitre 6. Oser la psychothérapie transpersonnelle par la pratique des états modifiés de conscience. In Les bases de la psychothérapie : Vol. 3e éd. (pp. 235–258). Dunod. https://www.cairn.info/les-bases- de-la-psychotherapie--9782100793501-p-235.htm
  33. Correia, A. S., & Vale, N. (2024). Advancements Exploring Major Depressive Disorder: Insights on Oxidative Stress, Serotonin Metabolism, BDNF, HPA Axis Dysfunction, and Pharmacotherapy Advances. International Journal of Translational Medicine, 4(1), 176-196. https://doi.org/10.3390/ijtm4010010
  34. Cristofori, I., Bulbulia, J., Shaver, J. H., Wilson, M., Krueger, F., & Grafman, J. (2016). Neural correlates of mystical experience. Neuropsychologia, 80, 212–220. https://doi.org/10.1016/j.neuropsychologia.2015.11.021
  35. Crosby, M. J. (2002). Mystical experiences, depression, well-being, and meaning (pp. 0829- 0829). National Library of Canada= Bibliothèque nationale du Canada, Ottawa. https://central.baclac.gc.ca/.item?id=MQ64735&op=pdf&app=Library&oclc_number =1006814672
  36. Crown, W. H., Finkelstein, S., Berndt, E. R., Ling, D., Poret, A. W., Rush, A. J., & Russell, J. M. (2002). The Impact of Treatment-Resistant Depression on Health Care Utilization and Costs. The Journal of Clinical Psychiatry, 63(11), 963–971.
  37. https://doi.org/10.4088/JCP.v63n1102
  38. Cui, L., Li, S., Wang, S., Wu, X., Liu, Y., Yu, W., Wang, Y., Tang, Y., Xia, M., & Li, B. (2024).
  39. Major depressive disorder: hypothesis, mechanism, prevention, and treatment. Signal Transduction and Targeted Therapy, 9(1), 1-32. https://doi.org/10.1038/s41392-024- 01738-y
  40. Cuijpers, P., Vogelzangs, N., Twisk, J., Kleiboer, A., Li, J., & Penninx, B. W. (2014). Comprehensive meta-analysis of excess mortality in depression in the general community versus patients with specific illnesses.American Journal of Psychiatry, 171(4), 453-462. https://doi.org/10.1176/appi.ajp.2013.13030325
  41. Davis, A. K., Barrett, F. S., May, D. G., Cosimano, M. P., Sepeda, N. D., Johnson, M. W., Finan, P. H., & Griffiths, R. R. (2021). Effects of psilocybin-assisted therapy on major depressive disorder: a randomized clinical trial. JAMA Psychiatry, 78(5), 481-489. DOI:10.1001/jamapsychiatry.2020.3285
  42. Devinsky, O., & Lai, G. (2008). Spirituality and Religion in Epilepsy. Epilepsy & Behavior, 12(4), 636–643. https://doi.org/10.1016/j.yebeh.2007.11.011
  43. De Vos, C. M., Mason, N. L., & Kuypers, K. P. (2021). Psychedelics and neuroplasticity: a systematic review unraveling the biological underpinnings of psychedelics. Frontiers in Psychiatry, 12, 724606. https://doi.org/10.3389/fpsyt.2021.724606
  44. Doblin, R. (1991). Pahnke’s «Good Friday experiment»: A long-term follow-up and methodological critique. The Journal of Transpersonal Psychology, 23(1). https://www.proquest.com/docview/1312139826/citation/A3E958AC6BD341BFPQ/1
  45. Dodd, S., Norman, T. R., Eyre, H. A., Stahl, S. M., Phillips, A., Carvalho, A. F., & Berk, M. (2023). Psilocybin in neuropsychiatry: a review of its pharmacology, safety, and efficacy. CNS spectrums, 28(4), 416-426. DOI: 10.1017/S1092852922000888
  46. Doss, M. K., Považan, M., Rosenberg, M. D., Sepeda, N. D., Davis, A. K., Finan, P. H., ... & Barrett, F. S. (2021). Psilocybin therapy increases cognitive and neural flexibility in patients with major depressive disorder. Translational Psychiatry, 11(1), 574. https://doi.org/10.1038/s41398-021-01706-y
  47. Dos Santos, R. G., & Hallak, J. E. C. (2020). Therapeutic use of serotoninergic hallucinogens: A review of the evidence and of the biological and psychological mechanisms. Neuroscience & Biobehavioral Reviews, 108, 423-434. https://doi.org/10.1016/j.neubiorev.2019.12.001
  48. Durisko, Z., Mulsant, B. H., & Andrews, P. W. (2015). An adaptationist perspective on the etiology of depression. Journal of Affective Disorders, 172, 315–323. https://doi.org/10.1016/j.jad.2014.09.032
  49. Dusi, N., Barlati, S., Vita, A., & Brambilla, P. (2015). Brain Structural Effects of Antidepressant Treatment in Major Depression. Current Neuropharmacology, 13(4), 458–465. https://doi.org/10.2174/1570159X1304150831121909
  50. Ewald, H., Klerings, I., Wagner, G., Heise, T. L., Stratil, J. M., Lhachimi, S. K., Hemkens, L. G., Gartlehner, G., Armijo-Olivo, S., & Nussbaumer-Streit, B. (2022). Searching two or more databases decreased the risk of missing relevant studies: a metaresearch study. Journal of Clinical Epidemiology, 149, 154-164. https://doi.org/10.1016/j.jclinepi.2022.05.022
  51. Fakhoury, M. (2016). Revisiting the Serotonin Hypothesis: Implications for Major Depressive Disorders. Molecular Neurobiology, 53(5), 2778–2786. https://doi.org/10.1007/s12035-015-9152-z
  52. Fournier, J. C., DeRubeis, R. J., Hollon, S. D., Dimidjian, S., Amsterdam, J. D., Shelton, R. C., & Fawcett, J. (2010). Antidepressant Drug Effects and Depression Severity: A Patient-Level Meta-analysis. JAMA, 303(1), 47–53.
  53. https://doi.org/10.1001/jama.2009.1943
  54. Gallagher, M., & Chiba, A. A. (1996). The amygdala and emotion. Current Opinion in
  55. Neurobiology, 6(2), 221–227. https://doi.org/10.1016/S0959-4388(96)80076-6
  56. Gashi, L., Sandberg, S., & Pedersen, W. (2021). Making “bad trips” good: How users of psychedelics narratively transform challenging trips into valuable
  57. experiences. International Journal of Drug Policy, 87, 102997.
  58. https://doi.org/10.1016/j.drugpo.2020.102997
  59. Gaynes, B. N., Lux, L., Gartlehner, G., Asher, G., Forman‐Hoffman, V., Green, J.& Lohr, K.
  60. N. (2020). Defining treatment‐resistant depression. Depression and Anxiety, 37(2),
  61. -145. https://doi.org/10.1002/da.22968
  62. Gedda, M. (2015). Traduction française des lignes directrices PRISMA pour l’écriture et la
  63. lecture des revues systématiques et des méta-analyses. Kinésithérapie, la Revue,
  64. (157), 39-44. DOI : 10.1016/j.kine.2014.11.004
  65. Gibson, T. B., Jing, Y., Carls, G. S., Kim, E., Bagalman, J. E., Burton, W. N., Tran, Q.-V.,
  66. Pikalov, A., & Goetzel, R. Z. (2010). Cost Burden of Treatment Resistance in Patients With Depression, The American Journal of Manged Care, 16(5), 370-377. ISSN: 1088- 0224 , 1936-2692; PMID: 20469957
  67. Gilman, S. E., Sucha, E., Kingsbury, M., Horton, N. J., Murphy, J. M., & Colman, I. (2017). Depression and mortality in a longitudinal study: 1952–2011. Canadian Medical Association Journal, 189(42), E1304–E1310. https://doi.org/10.1503/cmaj.170125
  68. Gold, P. W. (2021). Endocrine Factors in Key Structural and Intracellular Changes in Depression. Trends in Endocrinology & Metabolism, 32(4), 212–223. https://doi.org/10.1016/j.tem.2021.01.003
  69. Goodell, S., Druss, B. G., Walker, E. R. (2011). Mental disorders and medical comorbidity. Robert Wood Johnson Foundation, 2. https://www.researchgate.net/profile/Elizabeth- Walker- 15/publication/51220912_Mental_Disorders_and_Medical_Comorbidity/links/0a85e53c 973139cf16000000/Mental-Disorders-and-Medical-Comorbidity.pdf
  70. Goodwin, G. M., Aaronson, S. T., Alvarez, O., Arden, P. C., Baker, A., Bennett, J. C., ... & Malievskaia, E. (2022). Single-dose psilocybin for a treatment-resistant episode of major depression. New England Journal of Medicine, 387(18), 1637-1648. DOI: 10.1056/NEJMoa2206443
  71. Griffiths, R. R., Richards, W. A., McCann, U., & Jesse, R. (2006). Psilocybin can occasion mystical-type experiences having substantial and sustained personal meaning and spiritual significance. Psychopharmacology, 187(3), 268–283. https://doi.org/10.1007/s00213-006-0457-5
  72. Griffiths, R. R., Richards, W. A., Johnson, M. W., McCann, U. D., & Jesse, R. (2008). Mystical- type experiences occasioned by psilocybin mediate the attribution of personal meaning and spiritual significance 14 months later. Journal of psychopharmacology (Oxford, England), 22(6), 621–632. Kelmendi, B., Kaye, A. P., Pittenger, C., & Kwan, A. C. (2022). Psychedelics. Current Biology, 32(2), R63–R67. https://doi.org/10.1016/j.cub.2021.12.009
  73. Griffiths, R. R., Johnson, M. W., Carducci, M. A., Umbricht, A., Richards, W. A., Richards, B. D., Cosimano, M.P., & Klinedinst, M. A. (2016). Psilocybin produces substantial and sustained decreases in depression and anxiety in patients with life-threatening cancer: A randomized double-blind trial.Journal of Psychopharmacology,30(12), 1181-1197. https://doi.org/10.1177/0269881116675513
  74. Grof, S. (1980). Non-therapeutic uses of LSD. Alameda, CA: Hunter House. Retrieved.
  75. Gukasyan, N., Davis, A. K., Barrett, F. S., Cosimano, M. P., Sepeda, N. D., Johnson, M. W., & Griffiths, R. R. (2022). Efficacy and safety of psilocybin-assisted treatment for major depressive disorder: Prospective 12-month follow-up. Journal of Psychopharmacology, 36(2), 151-158. https://doi.org/10.1177/02698811211073759
  76. Gürhan, N., Beşer, N. G., Polat, Ü., & Koç, M. (2019). Suicide risk and depression in individuals with chronic illness. Community mental health journal, 55, 840-848. https://doi.org/10.1007/s10597-019-00388-7
  77. Gutiérrez-Rojas, L., Porras-Segovia, A., Dunne, H., Andrade-González, N., & Cervilla, J. A. (2020). Prevalence and correlates of major depressive disorder: A systematic review. Brazilian Journal of Psychiatry, 42, 657–672. https://doi.org/10.1590/1516-4446-2020- 0650
  78. Hadzic, M. (2011). Spirituality and mental health: Current research and future directions. Journal of Spirituality in Mental Health, 13(4), 223-235. https://doi.org/10.1080/19349637.2011.616080
  79. Handley, T., Rich, J., Davies, K., Lewin, T., & Kelly, B. (2018). The challenges of predicting suicidal thoughts and behaviours in a sample of rural Australians with depression. International Journal of Environmental Research and Public Health, 15(5), 928. DOI: 10.3390/ijerph15050928
  80. Harmer, C. J., Duman, R. S., & Cowen, P. J. (2017). How do antidepressants work? New perspectives for refining future treatment approaches. The Lancet Psychiatry, 4(5), 409– 418. https://doi.org/10.1016/S2215-0366(17)30015-9
  81. Harsanyi, S., Kupcova, I., Danisovic, L., & Klein, M. (2022). Selected biomarkers of depression: what are the effects of cytokines and inflammation? International Journal of Molecular Sciences, 24(1), 578. https://doi.org/10.3390/ijms24010578
  82. Hartogsohn, I. (2017). Constructing drug effects: A history of set and setting. Drug Science, Policy and Law, 3. DOI: 10.1177/2050324516683325
  83. Hawton, K., Casañas i Comabella, C., Haw, C., & Saunders, K. (2013). Risk factors for suicide in individuals with depression: A systematic review. Journal of Affective Disorders, 147(1), 17–28. https://doi.org/10.1016/j.jad.2013.01.004
  84. Heilman, J. E. (2022). The History, Legalization, and Potentials of Psilocybin-Assisted Psychotherapy. Journal of Scientific Exploration, 36(4). DOI: 10.31275/20222633
  85. Hofmann A. LSD Como descubrí el ácido y qué pasó después en el mundo (Mein Sorgenkind, 1979). Barcelona: Gedisa, 1997
  86. Johnson, M. W., & Griffiths, R. R. (2017). Potential Therapeutic Effects of Psilocybin. Neurotherapeutics, 14(3), 734–740. https://doi.org/10.1007/s13311-017-0542-y
  87. Johnstad, P. G. (2021). Day trip to hell: A mixed methods study of challenging psychedelic experiences. Journal of Psychedelic Studies, 5(2), 114-127. https://doi.org/10.1556/2054.2021.00155
  88. Joseph, R. (2001). The Limbic System and the Soul: Evolution and the Neuroanatomy of Religious Experience. Zygon, 36(1), 105–136. https://doi.org/10.1111/0591-2385.00343
  89. Joukamaa, M., HeliöVaara, M., Knekt, P., Aromaa, A., Raitasalo, R., & Lehtinen, V. (2001). Mental disorders and cause-specific mortality. British Journal of Psychiatry, 179(6), 498–502. https://doi.org/10.1192/bjp.179.6.498
  90. Jylkkä, J. (2021). Reconciling Mystical Experiences with Naturalistic Psychedelic Science: Reply to Sanders and Zijlmans. ACS Pharmacology & Translational Science, 4(4), 1468–1470. https://doi.org/10.1021/acsptsci.1c00137
  91. Kalin, N. H. (2020). Insights Into Suicide and Depression. American Journal of Psychiatry, 177(10), 877–880. https://doi.org/10.1176/appi.ajp.2020.20081207
  92. Kałuzna, A., Schlosser, M., Craste, E. G., Stroud, J., & Cooke, J. (2022). Being no one, being One: The role of ego-dissolution and connectedness in the therapeutic effects of psychedelic experience. Journal of Psychedelic Studies, 6(2), 111-136.
  93. https://doi.org/10.1556/2054.2022.00199
  94. Kamran, M., Bibi, F., Rehman, A., & Morris, D. W. (2022). Major Depressive Disorder:
  95. Existing Hypotheses about Pathophysiological Mechanisms and New Genetic
  96. Findings. Genes, 13(4), 4. https://doi.org/10.3390/genes13040646
  97. Kangaslampi, S. (2023). Association between mystical-type experiences under psychedelics and improvements in well-being or mental health–A comprehensive review of the evidence. Journal of Psychedelic Studies, 7(1), 18-28.
  98. https://doi.org/10.1556/2054.2023.00243
  99. Keller, J., Gomez, R., Williams, G., Lembke, A., Lazzeroni, L., Murphy, G. M., & Schatzberg,
  100. A. F. (2017). HPA axis in major depression: Cortisol, clinical symptomatology and genetic variation predict cognition. Molecular Psychiatry, 22(4), 527–536. https://doi.org/10.1038/mp.2016.120
  101. Kelmendi, B., Kaye, A. P., Pittenger, C., & Kwan, A. C. (2022). Psychedelics. Current Biology, 32(2), R63–R67. https://doi.org/10.1016/j.cub.2021.12.009
  102. Kennedy, S. H., & Ceniti, A. K. (2018). Unpacking major depressive disorder: from classification to treatment selection. The Canadian Journal of Psychiatry, 63(5), 308- 313. https://doi.org/10.1177/0706743717748883
  103. Kennis, M., Gerritsen, L., van Dalen, M., Williams, A., Cuijpers, P., & Bockting, C. (2020). Prospective biomarkers of major depressive disorder: a systematic review and meta- analysis.Molecular psychiatry,25(2), 321-338. https://doi.org/10.1038/s41380-019- 0585-z
  104. Kiecolt-Glaser, J. K., & Glaser, R. (2002). Depression and immune function: Central
  105. pathways to morbidity and mortality. Journal of Psychosomatic Research, 53(4), 873–
  106. https://doi.org/10.1016/S0022-3999(02)00309-4
  107. Ko, K., Knight, G., Rucker, J. J., & Cleare, A. J. (2022). Psychedelics, mystical experience, and therapeutic efficacy: a systematic review. Frontiers in Psychiatry, 13, 917199. https://doi.org/10.3389/fpsyt.2022.917199
  108. Koenig, H. G. (2010). Spirituality and mental health. International Journal of Applied Psychoanalytic Studies, 7(2), 116-122. DOI:10.1002/aps.239
  109. Lebedev, A. V., Lövdén, M., Rosenthal, G., Feilding, A., Nutt, D. J., & Carhart-Harris, R. L. (2015). Finding the self by losing the self: Neural correlates of ego-dissolution under psilocybin. Human Brain Mapping, 36(8), 3137–3153. https://doi.org/10.1002/hbm.22833
  110. Li, Z., Ruan, M., Chen, J., & Fang, Y. (2021). Major depressive disorder: advances in neuroscience research and translational applications. Neurosc. Bull.37, 863-880. https://doi.org/10.1007/s12264-021-00638-3
  111. Li, X., Mu, F., Liu, D., Zhu, J., Yue, S., Liu, M., Liu, Y., & Wang, J. (2022). Predictors of suicidal ideation, suicide attempt and suicide death among people with major depressive disorder: A systematic review and meta-analysis of cohort studies. Journal of Affective Disorders, 302, 332–351. https://doi.org/10.1016/j.jad.2022.01.103
  112. Liechti, M. E., Dolder, P. C., and Schmid, Y. (2017). Alterations of consciousness and mystical-type experiences after acute LSD in humans. Psychopharmacology, 234, 1499–1510. DOI: 10.1007/s00213-016-4453-0
  113. Lohoff, F. W. (2010). Overview of the Genetics of Major Depressive Disorder. Current Psychiatry Reports, 12(6), 539–546. https://doi.org/10.1007/s11920-010-0150-6
  114. Lowe, H., Toyang, N., Steele, B., Valentine, H., Grant, J., Ali, A., Ngwa, W., & Gordon, L. (2021). The therapeutic potential of psilocybin. Molecules, 26(10), 2948. https://doi.org/10.3390/molecules26102948
  115. Lukoff, D., & Lu, F. G. (1988). Transpersonal psychology research review: Topic: Mystical experience. The Journal of Transpersonal Psychology, 20(2). https://www.proquest.com/docview/1312109395/citation/87E4FC9C210A4C99PQ/1
  116. Ly, C., Greb, A. C., Cameron, L. P., Wong, J. M., Barragan, E. V., Wilson, P. C., Burbach, K. F., Soltanzadeh Zarandi, S., Sood, A., Paddy, M. R., Duim, W. C., Dennis, M. Y., McAllister, A. K., Ori-McKennedy, K. M., Gray, J. A., & Olson, D. E. (2018). Psychedelics Promote Structural and Functional Neural Plasticity. Cell Reports, 23, 3170-3182. https://doi.org/10.1016/j.celrep.2018.05.022
  117. Lynch, C. J., Gunning, F. M., & Liston, C. (2020). Causes and consequences of diagnostic heterogeneity in depression: paths to discovering novel biological depression subtypes. Biological psychiatry, 88(1), 83-94. https://doi.org/10.1016/j.biopsych.2020.01.012
  118. MacLean, K. A., Leoutsakos, J.-M. S., Johnson, M. W., & Griffiths, R. R. (2012). Factor Analysis of the Mystical Experience Questionnaire: A Study of Experiences Occasioned by the Hallucinogen Psilocybin. Journal for the Scientific Study of Religion, 51(4), 721–737. https://doi.org/10.1111/j.1468-5906.2012.01685.x
  119. Marx, W., Penninx, B. W. J. H., Solmi, M., Furukawa, T. A., Firth, J., Carvalho, A. F., & Berk, M. (2023). Major depressive disorder. Nature Reviews Disease Primers, 9(1), 44. https://doi.org/10.1038/s41572-023-00454-1
  120. Mateo, S. (2020). Procédure pour conduire avec succès une revue de littérature selon la méthode PRISMA. Kinésithérapie, la Revue, 20(226), 29-37. https://doi.org/10.1016/j.kine.2020.05.019
  121. Micheli, L., Ceccarelli, M., D’Andrea, G., & Tirone, F. (2018). Depression and adult neurogenesis: Positive effects of the antidepressant fluoxetine and of physical exercise. Brain Research Bulletin, 143, 181-193. https://doi.org/10.1016/j.brainresbull.2018.09.002
  122. Millière, R. (2017). Looking for the Self: Phenomenology, Neurophysiology and Philosophical Significance of Drug-induced Ego Dissolution. Frontiers in Human Neuroscience, 11. https://doi.org/10.3389/fnhum.2017.00245
  123. Mohan, A., Roberto, A. J., Mohan, A., Lorenzo, A., Jones, K., Carney, M. J., Lioger-Weyback, L., Hwang, S., & Lapidus, K. A. (2016). Focus: the aging brain: the significance of the default mode network (DMN) in neurological and neuropsychiatric disorders: a review. The Yale Journal of Bibiology and Medicine, 89(1), 49-57. PMID: 27505016; PMCID: PMC4797836
  124. Moher, D., Liberati, A., Tetzlaff, J., Altman, D. G., & PRISMA Group*, T. (2009). Preferred reporting items for systematic reviews and meta -analyses: the PRISMA statement. Annals of Internal Medicine, 151(4), 264-269.
  125. Momen, N. C., Plana-Ripoll, O., Agerbo, E., Christensen, M. K., Iburg, K. M., Laursen, T. M., Mortensen, P.B., Pedersen, C.B., Prior, A., Weye, N., & McGrath, J. J. (2022). Mortality associated with mental disorders and comorbid general medical conditions. JAMA Psychiatry, 79(5), 444-453. doi:10.1001/jamapsychiatry.2022.0347
  126. Moreton, S. G., Burden-Hill, A., & Menzies, R. E. (2023). Reduced death anxiety and obsessive beliefs as mediators of the therapeutic effects of psychedelics on obsessive compulsive disorder symptomology. Clinical Psychologist, 27(1), 58-73. https://doi.org/10.7326/0003-4819-151-4-200908180-00135
  127. Morshed, T., & Hayden, S. (2020). Google versus PubMed: comparison of Google and PubMed’s search tools for answering clinical questions in the emergency department. Annals of Emergency Medicine, 75(3), 408-415. https://doi.org/10.1016/j.annemergmed.2019.07.003
  128. Mosurinjohn, S., Roseman, L., & Girn, M. (2023). Psychedelic-induced mystical experiences: An interdisciplinary discussion and critique. Frontiers in Psychiatry, 14, 1077311. https://doi.org/10.3389/fpsyt.2023.1077311.
  129. Munkholm, K., Paludan-Müller, A. S., & Boesen, K. (2019). Considering the methodological limitations in the evidence base of antidepressants for depression: A reanalysis of a network meta-analysis. BMJ Open, 9(6). https://doi.org/10.1136/bmjopen-2018- 024886
  130. * Murphy, R., Kettner, H., Zeifman, R., Giribaldi, B., Kartner, L., Martell, J., ... & Carhart- Harris, R. (2022). Therapeutic alliance and rapport modulate responses to psilocybin assisted therapy for depression. Frontiers in Pharmacology, 12, 788155. https://doi.org/10.3389/fphar.2021.788155
  131. Nabeshima, T., & Kim, H.-C. (2013). Involvement of Genetic and Environmental Factors in the Onset of Depression. Experimental Neurobiology, 22(4), 235–243. https://doi.org/10.5607/en.2013.22.4.235
  132. Nakajima, S., Suzuki, T., Watanabe, K., Kashima, H., & Uchida, H. (2010). Accelerating response to antidepressant treatment in depression: A review and clinical suggestions. Progress in Neuro-Psychopharmacology and Biological Psychiatry, 34(2), 259–264. https://doi.org/10.1016/j.pnpbp.2009.12.001
  133. Nichols, D. E. (2016). Psychedelics. Pharmacological Reviews, 68(2), 264-355). DOI: 10.1124/pr.115.011478
  134. Nichols, D. E., & Walter, H. (2021). The history of psychedelics in psychiatry. Pharmacopsychiatry, 54(04), 151-166. DOI: 10.1055/a-1310-3990
  135. Nordin, M., Hlynsson, J. I., Håkansson, J., & Carlbring, P. (2024). A double-edged sword: Insights from practitioners on the short and long-term negative effects of psilocybin- assisted psychological interventions. Journal of Psychedelic Studies. https://doi.org/10.1556/2054.2024.00337
  136. Nour, M. M., Evans, L., Nutt, D., & Carhart-Harris, R. L. (2016). Ego-Dissolution and Psychedelics: Validation of the Ego-Dissolution Inventory (EDI). Frontiers in Human Neuroscience, 10. https://doi.org/10.3389/fnhum.2016.00269
  137. Ona, G. (2018). Inside bad trips: Exploring extra-pharmacological factors.Journal of Psychedelic Studies, 2(1), 53-60. DOI: 10.1556/2054.2018.001
  138. Østergaard, S. D., Jensen, S. O. W., & Bech, P. (2011). The heterogeneity of the depressive syndrome: when numbers get serious. Acta Psychiatrica Scandinavica, 124(6). Orsolini, L., Latini, R., Pompili, M., Serafini, G., Volpe, U., Vellante, F., Fornaro, M.,
  139. Valchera, A., Tomasetti, C., Fraticelli, S., Alessandrini, M., La Rovere, R., Trotta, S., Martinotti, G., Di Giannantonio, M., & De Berardis, D. (2020). Understanding the complex of suicide in depression: from research to clinics.Psychiatry Investigation, 17(3), 207. DOI:10.30773/pi.2019.0171
  140. Page, M. J., McKenzie, J. E., Bossuyt, P. M., Boutron, I., Hoffmann, T. C., Mulrow, C. D., ... & Moher, D. (2021). The PRISMA 2020 statement: an updated guideline for reporting systematic reviews. The BMJ, 372. DOI: 10.1186/s13643-021-01626-4
  141. Pahnke, W. N. 1969. The psychedelic mystical experience in the human encounter with death. Harvard Theological Review 62(1): 1–21. doi: 10.1017/S0017816000027577
  142. Paris J. The mistreatment of major depressive disorder. Can J Psychiatry. 2014 Mar;59(3):148-51. DOI: 10.1177/070674371405900306.
  143. Pearson, C., Siegel, J., & Gold, J. A. (2022). Psilocybin-assisted psychotherapy for depression: Emerging research on a psychedelic compound with a rich history. Journal of the Neurological Sciences, 434, 120096. https://doi.org/10.1016/j.jns.2021.120096
  144. Pečečnik, T. M., & Gostečnik, C. (2022). Use of spirituality in the treatment of depression: Systematic literature review. Psychiatric Quarterly, 93(1), 255-269. https://doi.org/10.1007/s11126-020-09881-9
  145. Perez-Caballero, L., Torres-Sanchez, S., Romero-López-Alberca, C., González-Saiz, F., Mico, J. A., & Berrocoso, E. (2019). Monoaminergic system and depression. Cell and Tissue Research, 377(1), 107–113. https://doi.org/10.1007/s00441-018-2978-8
  146. Persinger, M. A. (1983). Religious and mystical experiences as artifacts of temporal lobe function: A general hypothesis. Perceptual and Motor Skills, 57(3l), 1255-1262. https://www.demenzemedicinagenerale.net/pdf/Religious_and_mystical_experiences_ Persinger.pdf
  147. Pratt, L. A., Druss, B. G., Manderscheid, R. W., & Walker, E. R. (2016). Excess mortality due to depression and anxiety in the United States: Results from a nationally representative survey. General Hospital Psychiatry, 39, 39–45. https://doi.org/10.1016/j.genhosppsych.2015.12.003
  148. Preller, K. H., Duerler, P., Burt, J. B., Ji, J. L., Adkinson, B., Stämpfli, P., ... & Vollenweider, F. X. (2020). Psilocybin induces time-dependent changes in global functional connectivity. Biological Psychiatry, 88(2), 197-207. https://doi.org/10.1016/j.biopsych.2019.12.02
  149. Puchalski, C. M. (2012). Spirituality in the cancer trajectory. Annals of Oncology, 23, 49–55. https://doi.org/10.1093/annonc/mds088
  150. Qin, P., & Northoff, G. (2011). How is our self-related to midline regions and the default- mode network? Neuroimage, 57(3), 1221-1233. https://doi.org/10.1016/j.neuroimage.2011.05.028
  151. Richards, W. A. (1978). Mystical and Archetypal Experiences of Terminal Patients in DPT- Assisted Psychotherapy. Journal of Religion and Health, 17(2), 117–126. https://www.jstor.org/stable/27505442
  152. Revonsuo, A., Kallio, S., & Sikka, P. (2009). What is an altered state of consciousness? Philosophical Psychology, 22(2), 187-204. https://doi.org/10.1080/09515080902802850
  153. * Roseman, L., Nutt, D. J., & Carhart-Harris, R. L. (2018). Quality of acute psychedelic experience predicts therapeutic efficacy of psilocybin for treatment-resistant depression. Frontiers in pharmacology, 8, 309463. https://doi.org/10.3389/fphar.2017.00974
  154. Ross, S. (2018). Therapeutic use of classic psychedelics to treat cancer-related psychiatric distress. International Review of Psychiatry, 30(4), 317-330. https://doi.org/10.1080/09540261.2018.1482261
  155. Sacré, M., Lafontaine, D. & Toczek, M.-C. (2021). Comprendre et concevoir des revues systématiques de la littérature en sciences de l’éducation et de la formation. Nouveaux cahiers de la recherche en éducation, 23(2), 1–27. https://doi.org/10.7202/1085361ar
  156. Sanders, J. W., & Zijlmans, J. (2021). Moving Past Mysticism in Psychedelic Science. ACS Pharmacology & Translational Science, 4(3), 1253–1255. https://doi.org/10.1021/acsptsci.1c00097
  157. Sarkis-Onofre, R., Catalá-López, F., Aromataris, E., & Lockwood, C. (2021). How to properly use the PRISMA Statement. Systematic Reviews, 10, 1-3. https://doi.org/10.1186/s13643-021-01671-z
  158. Saveanu, R. V., & Nemeroff, C. B. (2012). Etiology of Depression: Genetic and Environmental Factors. Psychiatric Clinics of North America, 35(1), 51–71. https://doi.org/10.1016/j.psc.2011.12.001
  159. Savoldi, R., Roazzi, A., Escobar, J. A. C., Nour, M. M., & Carhart-Harris, R. (2023). The Structural Organization and Construct Validity Evidence of the Brazilian Versions of the Mysticism Scale and the Ego-Dissolution Inventory in a Major Religion of the Ayahuasca. International Journal of Latin American Religions, 7(2), 521–549. https://doi.org/10.1007/s41603-023-00203-y
  160. Scarpellini, G. (2020). Cohen’s kappa free calculator. https://idostatistics.com/cohenkappa- free-calculator/#calculator
  161. Smith, W. R., & Appelbaum, P. S. (2022). Novel ethical and policy issues in psychiatric uses of psychedelic substances. Neuropharmacology, 216, 109165. https://doi.org/10.1016/j.neuropharm.2022.109165
  162. Schmitt, Y. (2010). Les expériences mystiques peuvent-elles appartenir à des processus cognitifs?. ThéoRèmes. Penser le religieux. https://doi.org/10.4000/theoremes.62
  163. Schoenfeld, T. J., & Cameron, H. A. (2015). Adult neurogenesis and mental illness. Neuropsychopharmacology, 40(1), 113-128. DOI: 10.1038/npp.2014.230
  164. Scott, K. M., Lim, C., Al-Hamzawi, A., Alonso, J., Bruffaerts, R., Caldas-de-Almeida, J. M., Florescu, S., De Girolamo, G., Hu, C., De Jonge, P., Kawakami, N., Medina-Mora, M. E., Moskalewicz, J., Navarro-Mateu, F., O’Neill, S., Piazza, M., Posada-Villa, J., Torres, Y., & Kessler, R. C. (2016). Association of Mental Disorders With Subsequent Chronic Physical Conditions: World Mental Health Surveys From 17 Countries. JAMA Psychiatry, 73(2), 150. https://doi.org/10.1001/jamapsychiatry.2015.2688
  165. Sellers, E. M. (2017). Psilocybin: good trip or bad trip.Clinical Pharmacology & Therapeutics, 102(4), 580-584. DOI:10.1002/cpt.697
  166. Sepúlveda L'information psychiatrique https://doi.org/10.1684/ipe.2023.2662
  167. Sessa, B. (2016). The history of psychedelics in medicine.Handbuch Psychoaktive Substanzen, 1-26. DOI 10.1007/978-3-642-55214-4_96-1
  168. Shadrina, M., Bondarenko, E. A., & Slominsky, P. A. (2018). Genetics Factors in Major Depression Disease. Frontiers in Psychiatry, 9. https://doi.org/10.3389/fpsyt.2018.0033
  169. Skaper, S. D. (2018). Neurotrophic Factors: An Overview. In S. D. Skaper (A c. Di), Neurotrophic Factors: Methods and Protocols, 1–17. Springer. https://doi.org/10.1007/978-1-4939-7571-6_1
  170. Smigielski, L., Scheidegger, M., Kometer, M., & Vollenweider, F. X. (2019). Psilocybin- assisted mindfulness training modulates self-consciousness and brain default mode network connectivity with lasting effects. NeuroImage, 196, 207-215. https://doi.org/10.1016/j.neuroimage.2019.04.009
  171. Snell, T. L., & Simmonds, J. G. (2015). Mystical experiences in nature: Comparing outcomes for psychological well-being and environmental behaviour. Archive for the Psychology of Religion, 37(2), 169-184. DOI: 10.1163/15736121-12341303
  172. Souery, D., Oswald, P., Massat, I., Bailer, U., Bollen, J., Demyttenaere, K., Kasper, S., Lecrubier, Y., Montgomery, S., Serretti, A., Zohar, J., & Mendlewicz, J. (2007). Clinical factors associated with treatment resistance in major depressive disorder: results from a European multicenter study. Journal of Clinical Psychiatry, 68(7), 1062-1070 DOI: 10.4088/JCP.v68n0713
  173. Souery, D., Papakostas, G. I., & Trivedi, M. H. (2006). Treatment-resistant depression. Journal of Clinical Psychiatry, 67, 16. ISSN: 1302-0099 , 2146-7153
  174. Sterne, J. A. C., Higgins J.P.T., Elbers, R. G., Reeves, B. C., and the development group for ROBINS-I. Risk Of Bias In Non-randomized Studies of Interventions (ROBINS-I): detailed guidance, updated 12 October
  175. , S. (2023). Psychédéliques: à 80 ans du début de l’histoire.
  176. , 99, 733-740.
  177. Sterne, J. A. C., Savović, J., Page, M. J., Elbers, R. G., Blencowe, N. S., Boutron, I., Cates, C. J., Cheng, H-Y., Corbett, M. S., Eldridge, S. M., Hernán, M. A., Hopewell, S., Hróbjartsson, A., Junqueira, D. R., Jüni, P., Kirkham, J. J., Lasserson, T., Li, T., McAleenan, A., Reeves, B. C., Shepperd, S., Shrier, I., Stewart, L. A. , Tilling, K., White, I. R., Whiting, P. F., Higgins, J. P. T. RoB 2: a revised tool for assessing risk of bias in randomised trials. BMJ 2019; 366: l4898.
  178. Stoliker, D., Egan, G. F., Friston, K. J., & Razi, A. (2022). Neural mechanisms and psychology of psychedelic ego dissolution. Pharmacological Reviews, 74(4), 876-917. https://doi.org/10.1124/pharmrev.121.000508
  179. Straumann, I., Holze, F., Becker, A. M., Ley, L., Halter, N., & Liechti, M. E. (2024). Safety pharmacology of acute psilocybin administration in healthy partecipant-e- s. Neuroscience Applied, 3, 104060. https://doi.org/10.1016/j.nsa.2024.104060
  180. Studerus, E., Gamma, A., & Vollenweider, F. X. (2010). Psychometric Evaluation of the Altered States of Consciousness Rating Scale (OAV). PLOS ONE, 5(8), e12412. https://doi.org/10.1371/journal.pone.0012412
  181. Studerus, E., Kometer, M., Hasler, F., & Vollenweider, F. (2011). Acute, Subacute and Long- Term Subjective Effects of Psilocybin in Healthy Humans: A Pooled Analysis of Experimental Studies. Journal of psychopharmacology (Oxford, England), 25, 1434– 1452. https://doi.org/10.1177/0269881110382466
  182. Studerus, E., Gamma, A., Kometer, M., & Vollenweider, F. X. (2012). Prediction of Psilocybin Response in Healthy Volunteers. PLOS ONE, 7(2), e30800. https://doi.org/10.1371/journal.pone.0030800
  183. Sueur, C. (2017). La recherche sur les capacités thérapeutiques des «substances hallucinogènes ». Chimères, 91(1), 120–138. https://doi.org/10.3917/chime.091.0120
  184. Sugrim, S. (2023). APA PsycINFO on EBSCO. The Charleston Advisor, 25(1), 5–8. https://doi.org/10.5260/chara.25.1.02
  185. Tang, M., Lin, W., Pan, Y., Guan, X., & Li, Y. (2016). Hippocampal neurogenesis dysfunction linked to depressive-like behaviors in a neuroinflammation induced model of depression. Physiology & Behavior, 161, 166–173. https://doi.org/10.1016/j.physbeh.2016.04.034
  186. Taves, A. (2020). Mystical and Other Alterations in Sense of Self: An Expanded Framework for Studying Nonordinary Experiences. Perspectives on Psychological Science, 15(3), 669–690. https://doi.org/10.1177/1745691619895047
  187. Tupper, K. W., Wood, E., Yensen, R., & Johnson, M. W. (2015). Psychedelic medicine: A re- emerging therapeutic paradigm. CMAJ, 187(14), 1054–1059. https://doi.org/10.1503/cmaj.141124
  188. Turecki, G., Brent, D. A., Gunnell, D., O’Connor, R. C., Oquendo, M. A., Pirkis, J., & Stanley, B. H. (2019). Suicide and suicide risk. Nature Reviews Disease Primers, 5(1), 74. https://doi.org/10.1038/s41572-019-0121-0
  189. Tylš, F., Páleníček, T., & Horáček, J. (2014). Psilocybin – Summary of knowledge and new perspectives. European Neuropsychopharmacology, 24(3), 342–356. https://doi.org/10.1016/j.euroneuro.2013.12.006
  190. Van Court, R. C., Wiseman, M. S., Meyer, K. W., Ballhorn, D. J., Amses, K. R., Slot, J. C., Dentinger, B.T.M., Garibay-Orijel, R., & Uehling, J. K. (2022). Diversity, biology, and history of psilocybin-containing fungi: suggestions for research and technological development. Fungal Biology, 126(4), 308-319. https://doi.org/10.1016/j.funbio.2022.01.003
  191. Walker, E. R., McGee, R. E., & Druss, B. G. (2015). Mortality in Mental Disorders and Global Disease Burden Implications: A Systematic Review and Meta-analysis. JAMA Psychiatry, 72(4), 334–341. https://doi.org/10.1001/jamapsychiatry.2014.2502
  192. Weiss, B., Roseman, L., Giribaldi, B., Nutt, D. J., Carhart-Harris, R. L., & Erritzoe, D. (2024). Unique Psychological Mechanisms Underlying Psilocybin Therapy Versus Escitalopram Treatment in the Treatment of Major Depressive Disorder. International Journal of Mental Health and Addiction, 1-36. https://doi.org/10.1007/s11469-024- 01253-9
  193. Willner, P., Scheel-Krüger, J., & Belzung, C. (2013). The neurobiology of depression and antidepressant action. Neuroscience & Biobehavioral Reviews, 37(10), 2331–2371. https://doi.org/10.1016/j.neubiorev.2012.12.007
  194. Winkelman, M. (2014). Psychedelics as medicines for substance abuse rehabilitation: evaluating treatments with LSD, Peyote, Ibogaine and Ayahuasca. Current drug abuse reviews, 7(2), 101-116. https://www.researchgate.net/profile/Michael- Winkelman/publication/270654137_Psychedelics_as_Medicines_for_Substance_Abus e_Rehabilitation_Evaluating_Treatments_with_LSD_Peyote_Ibogaine_and_Ayahuasc a/links/5523126b0cf29dcabb0ee134/Psychedelics-as-Medicines-for-Substance-Abuse- Rehabilitation-Evaluating-Treatments-with-LSD-Peyote-Ibogaine-and-Ayahuasca.pdf
  195. Winkelman, M. J. (2021). The evolved psychology of psychedelic set and setting: Inferences regarding the roles of shamanism and entheogenic ecopsychology. Frontiers in pharmacology, 12, 619890. https://doi.org/10.3389/fphar.2021.619890
  196. World Health Organization. (2023, August 28). Suicide. World Health Organization. https://www.who.int/news-room/fact-sheets/detail/suicide
  197. Wulff, A. B., Nichols, C. D., & Thompson, S. M. (2023). Preclinical perspectives on the mechanisms underlying the therapeutic actions of psilocybin in psychiatric disorders. Neuropharmacology, 231, 109504. https://doi.org/10.1016/j.neuropharm.2023.109504Get
  198. Yaden, D. B., Haidt, J., Hood Jr, R. W., Vago, D. R., & Newberg, A. B. (2017). The varieties of self-transcendent experience. Review of General Psychology, 21(2), 143-160. https://doi.org/10.1037/gpr0000102
  199. Yonker, J. E., Schnabelrauch, C. A., & DeHaan, L. G. (2012). The relationship between spirituality and religiosity on psychological outcomes in adolescents and emerging adults: A meta-analytic review. Journal of Adolescence, 35(2), 299–314. https://doi.org/10.1016/j.adolescence.2011.08.010
  200. * Zeifman, R. J., Wagner, A. C., Monson, C. M., & Carhart-Harris, R. L. (2023). How does psilocybin therapy work? An exploration of experiential avoidance as a putative mechanism of change. Journal of Affective Disorders, 334, 100-112. https://doi.org/10.1016/j.jad.2023.04.105
  201. Zhdanava, M., Pilon, D., Ghelerter, I., Chow, W., Joshi, K., Lefebvre, P., & Sheehan, J. J. (2021). The Prevalence and National Burden of Treatment-Resistant Depression and Major Depressive Disorder in the United States. The Journal of Clinical Psychiatry, 82(2), 29169. https://doi.org/10.4088/JCP.20m13699